Structural changes from wild-type define tumor-rejecting neoantigens.

ABSTRACT:

Background

Challenges in predicting which neoantigens mediate tumor rejection limit the efficacy of neoantigen vaccines to treat cancers, especially for cancers with a high mutational burden like cutaneous squamous cell carcinoma (cSCC). Only a small portion of neoantigens prioritized by current methods elicit effective T cell responses, demonstrating the critical need for improved criteria for the prediction of tumor-rejecting neoantigens.

Methods

Publicly available human cSCC datasets were used to assess the frequency of shared mutations between patients. A transplantable ultraviolet light-induced mouse model of cSCC was generated. The mutational signature and driver mutations in the mouse model were compared with human tumors. Neoantigens were prioritized in the mouse mod

SUBMITTER: Adams AC 

PROVIDER: S-EPMC12548620 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature